Vivos Therapeutics Inc Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)4.33 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $0.15Price as of 30 Sep 2026 Data confidenceNot applicable Market Cap $3M Enterprise Value $9.3M Shares Outstanding 17.6M diluted Next Earnings Date16 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Vivos Therapeutics is undergoing a critical business model transition, shifting away from its legacy dentist-focused VIP enrollment model toward a medical provider-focused approach and direct clinical operations via its Sleep Center of Nevada (SCN) acquisition. While this pivot has accelerated top-line growth (70% YoY revenue increase in Q1 2026) and expanded gross margins to 60%, it has also significantly increased operating expenses and cash burn. The company faces severe liquidity constraints, a substantial stockholders' equity deficit, and active Nasdaq delisting warnings regarding both its equity shortfall and minimum bid price. Consequently, while the clinical efficacy of its FDA-cleared CARE devices remains a strong long-term asset, the near-term financial and regulatory risks warrant a cautious Hold stance. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$0.75 Mean target$2.12 High · most bullish analyst$3.10 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The company fails to secure sufficient capital on reasonable terms, leading to severe dilution from emergency financing measures or delisting from the Nasdaq Capital Market. Operational cash burn remains unsustainably high, and the transition away from the legacy VIP model completely erodes legacy product revenues before SCN-related services can fully offset the loss. Base CaseCentral scenario The company successfully leverages its SCN acquisition and medical provider alliances to sustain high double-digit revenue growth. However, ongoing high operating expenses and professional fees delay cash flow positivity. The company manages to maintain its Nasdaq listing through highly dilutive equity issuances, debt-to-equity swaps, and a potential reverse stock split, keeping the stock range-bound. Bull CaseUpside scenario Vivos' strategic pivot to a vertically integrated medical-provider model, anchored by the acquisition of The Sleep Center of Nevada and the AIM Florida collaboration, significantly expands direct patient access and introduces high-margin diagnostic and treatment revenue streams, accelerating the path to cash flow positivity. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |